Rocket Pharmaceuticals Securities Class Action Lawsuit Filed

Strategic Insights -

Rocket Pharmaceuticals' securities class action lawsuit was filed for investors who purchased Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025, due to alleged false and misleading statements made by the company about the safety and clinical trial protocol of its RP-A501 treatment. The lawsuit claims that Rocket Pharmaceuticals concealed material adverse facts, including the risk of Serious Adverse Events, including death of participants enrolled in the study, without updating shareholders. As a result, investors suffered damages and may be entitled to compensation.

Key Takeaways:

  • The lawsuit covers investors who purchased Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.
  • The lawsuit alleges that Rocket Pharmaceuticals made false and misleading statements about the safety and clinical trial protocol of its RP-A501 treatment.
  • The company allegedly concealed material adverse facts, including the risk of Serious Adverse Events, including death of participants enrolled in the study.
  • The lawsuit claims that investors suffered damages due to purchasing Rocket Pharmaceuticals securities at artificially inflated prices.
  • Lead plaintiff must move the Court no later than August 11, 2025, for the litigation to proceed.
  • Rosen Law Firm represents investors throughout the globe, with a track record of success in securities class actions and shareholder derivative litigation.
  • The firm has secured hundreds of millions of dollars for investors, including the largest ever securities class action settlement against a Chinese Company at the time.
  • The law firm has been ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017 and has several attorneys recognized by Lawdragon and Super Lawyers.

Statistics:

  • The lawsuit covers a period of approximately 3 months (February 27, 2025 to May 26, 2025).
  • The number of investors affected by the alleged false and misleading statements is unknown.
  • The potential damages experienced by investors are also unknown.
  • Rosen Law Firm has secured over $438 million for investors in 2019 alone.
  • The firm has a track record of securing hundreds of millions of dollars for investors in various cases.

Sources:

  • Newsfile Corp.
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)
  • Rosen Law Firm
  • ISS Securities Class Action Services
  • Lawdragon
  • Super Lawyers